Background: Rheumatoid arthritis (RA) is considered by symmetrical peripheral arthritis, synovitis & joint destruction. Statins, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme ductase, significantly reduce coronary artery disease by helping to lower plasma low-density lipoprotein cholesterol levels. Experimental studies, more recently, several clinical trials have convincingly shown that statins play a vital role in Rheumatoid arthritis, primarily due to their anti-inflammatory and immunomodulatory properties.

Aim: To assess the effectiveness of statin adjunctive therapy versus standard treatment with disease-modifying antirheumatic drugs (DMARDs) in patients with RA.

Methods: In this research, patients with a diagnosis of RA among the ages of 30 and 65 years were recruited according to the "Open Rheumatoid Pathologist" inclusion criteria. Among the selected patients, two distinct patient strata were identified. Strata 1 included 40 RA patients who are currently taking DMARDs with statins; Strata 2 included 40 patients with RA who are currently receiving DMARDs; observed for 6 months; To compare the outcomes of RA in both strata, standard parameters DAS28, ESR, and CRP were estimated.

Results: There were eighty subjects included in the research; this study demonstrated a significant beneficial role of additional statin drugs when administered alongside conventional DMARDs in patients with active RA. The clinical significance index of disease activity in RA was significantly (P <0.05) lower in the statin adjuvant strata (strata 1) than in the conventional DMARD treatment strata (P <0.05). Strata 2) after 6 months of Continuous treatment. Two other important biochemical markers of RA disease activity, ESR and CRP, were also significantly lower in RA patients taking statins (strata 1) (P <0.05). Compared to strata 2, which includes only RA. the patient was treated with a conventional DMARD without statins.

Conclusion: The results suggest a supportive and possibly beneficial role for statin therapy in cases of active RA, leading to clinically and biochemically significant improvements.

Keywords: inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme is reductase, disease activity indicator 28,